Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update PR Newswire CRANBURY, N.J., May 14...
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 PR...
Palatin Technologies Announces Closing of Reduced Public Offering PR Newswire CRANBURY, N.J., May 8, 2025...
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye...
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice PR...
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice PR Newswire CRANBURY, N.J., May...
Palatin Technologies Announces Pricing of up to $23 Million Public Offering PR Newswire CRANBURY, N.J., May 7...
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a...
Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical...
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide...
Palatin Appeals NYSE American Notice of Delisting PR Newswire CRANBURY, N.J., April 14, 2025 Company working...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads